2010
DOI: 10.1200/jco.2009.23.7370
|View full text |Cite|
|
Sign up to set email alerts
|

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Abstract: PURPOSE Preclinical data suggest a contribution of the immune system to chemotherapy response. In this study, we investigated the prespecified hypothesis that the presence of a lymphocytic infiltrate in cancer tissue predicts the response to neoadjuvant chemotherapy. METHODS We investigated intratumoral and stromal lymphocytes in a total of 1,058 pretherapeutic breast cancer core biopsies from two neoadjuvant anthracycline/taxane-based studies (GeparDuo, n = 218, training cohort; and GeparTrio, n = 840, valida… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

85
1,303
8
21

Year Published

2010
2010
2017
2017

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 1,549 publications
(1,417 citation statements)
references
References 35 publications
85
1,303
8
21
Order By: Relevance
“…It is well known that the achievement of pCR represents the main prerequisite to improve both disease-free survival and overall survival (OS) [20]. Several studies have shown that higher TIL infiltration in the pretreatment core biopsy specimen is a predictor of response to neoadjuvant chemotherapy [21][22][23]. Also in this case, TILs seems to predict pCR, especially in TNBC and HER2-positive BC, even if this finding did not constantly emerge in all studies [24].…”
Section: Introductionmentioning
confidence: 90%
See 1 more Smart Citation
“…It is well known that the achievement of pCR represents the main prerequisite to improve both disease-free survival and overall survival (OS) [20]. Several studies have shown that higher TIL infiltration in the pretreatment core biopsy specimen is a predictor of response to neoadjuvant chemotherapy [21][22][23]. Also in this case, TILs seems to predict pCR, especially in TNBC and HER2-positive BC, even if this finding did not constantly emerge in all studies [24].…”
Section: Introductionmentioning
confidence: 90%
“…1) [16-18, 21-23, 33, 34]. Of these, 4 RCTs (1,694 patients) [21][22][23]33] were conducted in the neoadjuvant setting and 4 RCTs (3,820 patients) [16][17][18]34] were conducted in the adjuvant setting. Selected arms of neoadjuvant trials and their characteristics are listed in Table 1.…”
Section: Selected Trialsmentioning
confidence: 99%
“…The first randomized controlled trial indicated that a relationship exists between increased numbers of TILs and pCR rates. 111 Podshivalova et al 112 suggested that miRNA have an important role in T-lymphocyte activation and also described a mechanism for regulating the impact of miRNA. Jasinski-Bergner reported that natural killer cell and CD8-positive T-lymphocyte ligands are both regulated by the number of miRNAs.…”
Section: Mirna In Triple-negative Breast Cancermentioning
confidence: 99%
“…[2][3][4][5][6] These results point to a hitherto poorly understood role for anticancer immune responses in determining the long-term success of chemotherapy, a notion that is in line with abundant clinical data indicating that tumor infiltration by cytotoxic T lymphocytes influences disease outcome. [7][8][9][10] Cancer cells respond to some chemotherapeutics such as anthracyclines and oxaliplatin by undergoing an immunogenic form of cell death, meaning that such dying cells become able to induce a potent cellular immune response on subcutaneous injection into immunocompetent mice. 1,5,11 However, cell death as induced by many other agents including mitomycin C and cisplatin is unable to elicit such an anticancer immune response in vivo, [12][13][14] pointing to major differences in the capacity of distinct agents to promote immunogenic cell death (ICD).…”
mentioning
confidence: 99%